STOCK TITAN
  1. Home
  2. Sec-filings
  3. ISCO
  4. [8-K] International Stem Cell CORP Reports Material Event

[8-K] International Stem Cell CORP Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

International Stem Cell Corporation reported voting results from its Annual Meeting of Stockholders held on June 11, 2026. Stockholders voted on the election of directors described in the proxy dated April 24, 2026.

All named director candidates, including Andrey Semechkin, Russell Kern, Donald A. Wright, and Paul V. Maier, were elected. Support was strong, with 2,457,143 votes "for" Semechkin and Kern, and over 9.28 million votes "for" Wright and Maier against relatively small withheld votes. The company reported no broker non-votes in this election.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Votes for Andrey Semechkin 2,457,143 votes Director election at Annual Meeting on June 11, 2026
Votes for Russell Kern 2,457,143 votes Director election at Annual Meeting on June 11, 2026
Votes for Donald A. Wright 9,288,444 votes for; 30,590 withheld Director election at Annual Meeting on June 11, 2026
Votes for Paul V. Maier 9,288,500 votes for; 30,534 withheld Director election at Annual Meeting on June 11, 2026
Broker non-votes none Director election voting results
Annual Meeting of Stockholders regulatory
"held its Annual Meeting of Stockholders on June 11, 2026"
definitive proxy statement regulatory
"described in more detail in the Company’s definitive proxy statement dated April 24, 2026"
A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.
Broker Non-Votes regulatory
"Broker Non-Votes: none"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
withheld financial
"Donald A. Wright | 9,288,444 | | 30,590 |"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0001355790 0001355790 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): June 11, 2026

  

 

 

INTERNATIONAL STEM CELL CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware 000-51891 20-4494098

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

 

9745 Businesspark Ave, San Diego, California 92131

(Address of principal executive offices, including zip code)

 

(760) 940-6383

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CAR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

None N/A N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

   
 

 

ITEM 5.07 Submission of Matters to a Vote of Security Holders

 

International Stem Cell Corporation (the “Company”) held its Annual Meeting of Stockholders on June 11, 2026. The stockholders considered one proposal, which is described in more detail in the Company’s definitive proxy statement dated April 24, 2026.

 

Proposal 1: Election of four directors to hold office until the 2027 Annual Meeting:

 

  A. Directors elected by holders of Series D Preferred Stock:

 

  FOR   WITHHELD  
Andrey Semechkin 2,457,143   0  
Russell Kern 2,457,143   0  

  

  B. Directors elected by holders of all shares of stock (including shares of preferred stock voting on an as-converted basis):

 

  FOR   WITHHELD  
Donald A. Wright 9,288,444   30,590  
Paul V. Maier 9,288,500   30,534  

 

Broker Non-Votes: none

 

All of the foregoing candidates were elected.

 

 

 

 

 

 

 

 

 

 

 

 2 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  INTERNATIONAL STEM CELL CORPORATION
     
     
Date: June 12, 2026 By: /s/ Russell Kern
    Russell Kern
   

Executive Vice President,

Chief Scientific Officer and

Principal Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents